Numinus Wellness chief medical officer Dr. Evan Wood cautions that it’s not a cure for everybody—but trials have shown statistically significant results
The market capitalizations of Aurora, Tilray, Canopy Growth, Aphria, Cronos Group, and Hexo are all sharply higher than they were seven days earlier.
Most recently, Wood has headed the British Columbia Centre on Substance Use, which offers clinical guidance to medical practitioners
Earlier this month, one financial writer described the company as the poster child of the legal weed industry’s woes.
Our roundup of cannabis stocks shows some improvement for Canopy Growth Corporation after a shakeup in the corporate office, but it was humdrum week for Tilray, Cronos Group, and Aphria.
There’s also a statewide proposal, IP 34, seeking access to licensed psilocybin therapy in Oregon.